natalizumab vs Tyruko (natalizumab-sztn)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: α4 integrin · full Multiple Sclerosis pipeline

natalizumab · Tysabri

Marketed by Biogen

Approved in Multiple Sclerosismonoclonal antibody (humanized IgG4)
Reliable signal

NCT00027300 · Phase 3 · completed

The trial was large, randomized, blinded, and placebo-controlled, with hard clinical endpoints of relapse rate and disability progression, and natalizumab significantly reduced both (68% relapse-rate reduction and 42% reduction in sustained disability progression, both P<0.001).

Next expected readout: October 2027 · NCT05418010 (registry estimate)

Reported efficacy

The primary objectives of this study are to determine whether natalizumab, when compared with placebo, is effective in reducing the rate of clinical relapses at 1 year and, in slowing the progression of disability at 2 years. (1 year and 2 years): Sustained disability progression at 2 years reduced 42% (hazard ratio 0.58, 95% CI 0.43-0.77, P<0.001; cumulative probability 17% natalizumab vs 29% placebo); clinical relapse rate at 1 year reduced 68% (P<0.001). (met)

Result source: NCT00027300

Tyruko (natalizumab-sztn)

Marketed by Sandoz Group AG and partners

Approved in Multiple Sclerosismonoclonal antibody (biosimilar)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: October 2027 · NCT05418010 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointnatalizumabTyruko (natalizumab-sztn)
Annualised relapse rate0.5 vs 1.7−1.2 vs placebowk 24 · n 9NCT01440101—Not reported
Free of 3-month confirmed disability progression (%)—Not posted · NCT00027300—Not reported
New or enlarging T2 lesions0.3 vs 1.1−0.8 vs placebowk 24 · n 47NCT01440101—Not reported

Annualised relapse rate

natalizumab
0.5 vs 1.7−1.2 vs placebowk 24 · n 9NCT01440101
Tyruko (natalizumab-sztn)
—Not reported

Free of 3-month confirmed disability progression (%)

natalizumab
—Not posted · NCT00027300
Tyruko (natalizumab-sztn)
—Not reported

New or enlarging T2 lesions

natalizumab
0.3 vs 1.1−0.8 vs placebowk 24 · n 47NCT01440101
Tyruko (natalizumab-sztn)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Tyruko (natalizumab-sztn): no structured comparison results are available for Multiple Sclerosis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. natalizumab: 4 of 4 rows · Tyruko (natalizumab-sztn): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricnatalizumab
Dropout rate
—IV Q4Wa
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 29 more results
—IV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—IV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—IV Q6W then SC Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—SC Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—SC Q6W then IV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—IV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0%
NCT03046251 · Phase 4 · registry result, not featured evidence
12.1%
NCT00871780 · Phase 4 · registry result, not featured evidence
20%
NCT00536120 · Phase 4 · registry result, not featured evidence · combination
—300 mg IV monthly
NCT00306592 · Phase 3 · registry result, not featured evidence
2.1%Double-Blind Natalizumab
NCT01440101 · Phase 2/3 · registry result, not featured evidence
16.7%Open Label Natalizumab
NCT01440101 · Phase 2/3 · registry result, not featured evidence
59.8%
NCT01416155 · Phase 2 · registry result, not featured evidence
—300 mg IV every 4 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—300 mg IV every 4 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—300 mg IV every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—300 mg IV every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—300 mg SC every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—300 mg SC every 4 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—300 mg SC every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—300 mg SC every 4 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—150 mg IV every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—150 mg SC every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—150 mg IV every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—150 mg SC every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
4.4%
NCT01071083 · Phase 2 · registry result, not featured evidence
18.6%
NCT00516893 · Phase 2 · registry result, not featured evidence
25%
NCT01071512 · Phase na · registry result, not featured evidence
66.7%
NCT01455220 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—IV Q4Wa
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 29 more results
—IV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—IV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—IV Q6W then SC Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—SC Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—SC Q6W then IV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—IV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—
NCT03046251 · Phase 4 · registry result, not featured evidence
2.7%
NCT00871780 · Phase 4 · registry result, not featured evidence
—
NCT00536120 · Phase 4 · registry result, not featured evidence · combination
—300 mg IV monthly
NCT00306592 · Phase 3 · registry result, not featured evidence
0%Double-Blind Natalizumab
NCT01440101 · Phase 2/3 · registry result, not featured evidence
16.7%Open Label Natalizumab
NCT01440101 · Phase 2/3 · registry result, not featured evidence
8.2%
NCT01416155 · Phase 2 · registry result, not featured evidence
—300 mg IV every 4 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—300 mg IV every 4 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—300 mg IV every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—300 mg IV every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—300 mg SC every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—300 mg SC every 4 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—300 mg SC every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—300 mg SC every 4 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—150 mg IV every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—150 mg SC every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—150 mg IV every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—150 mg SC every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
0%
NCT01071083 · Phase 2 · registry result, not featured evidence
2.7%
NCT00516893 · Phase 2 · registry result, not featured evidence
5%
NCT01071512 · Phase na · registry result, not featured evidence
—
NCT01455220 · Phase na · registry result, not featured evidence
Serious AEs
6.9%IV Q4Wa
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 29 more results
6.8%IV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
1.5%IV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—IV Q6W then SC Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
3%SC Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—SC Q6W then IV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
1.9%IV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0%
NCT03046251 · Phase 4 · registry result, not featured evidence
3.2%
NCT00871780 · Phase 4 · registry result, not featured evidence
10%
NCT00536120 · Phase 4 · registry result, not featured evidence · combination
5.6%300 mg IV monthly
NCT00306592 · Phase 3 · registry result, not featured evidence
14.9%Double-Blind Natalizumab
NCT01440101 · Phase 2/3 · registry result, not featured evidence
16.7%Open Label Natalizumab
NCT01440101 · Phase 2/3 · registry result, not featured evidence
29.9%
NCT01416155 · Phase 2 · registry result, not featured evidence
0%300 mg IV every 4 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
13%300 mg IV every 4 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
0%300 mg IV every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
7.7%300 mg IV every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
2.4%300 mg SC every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
2.9%300 mg SC every 4 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
5.7%300 mg SC every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
8.9%300 mg SC every 4 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
2.4%150 mg IV every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
6.3%150 mg SC every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
8.5%150 mg IV every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
2.6%150 mg SC every 12 weeks
NCT01405820 · Phase 2 · registry result, not featured evidence
—
NCT01071083 · Phase 2 · registry result, not featured evidence
6.3%
NCT00516893 · Phase 2 · registry result, not featured evidence
0%
NCT01071512 · Phase na · registry result, not featured evidence
0%
NCT01455220 · Phase na · registry result, not featured evidence
Most frequent reported AEs
IV Q4Wa
nasopharyngitis 13%
headache 9.3%
urinary tract infection 7.7%
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 26 more results
IV Q6W
nasopharyngitis 10.8%
headache 10.4%
fatigue 10%
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
IV Q6W
covid-19 20.6%
headache 5.1%
urinary tract infection 5.1%
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
SC Q6W
covid-19 23.5%
nasopharyngitis 9.8%
arthralgia 6.1%
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
IV Q6W
covid-19 12%
urinary tract infection 3.8%
fall 3.2%
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
ms relapse 50%
NCT03046251 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 8.3%
headache 6.4%
NCT00871780 · Phase 4 · registry result, not featured evidence
multiple sclerosis relapse 16.7%
influenza 13.3%
injection site erythrema 13.3%
NCT00536120 · Phase 4 · registry result, not featured evidence · combination
300 mg IV monthly
multiple sclerosis relapse 14.3%
nasopharyngitis 12.9%
upper respiratory tract infection 10.9%
NCT00306592 · Phase 3 · registry result, not featured evidence
nasopharyngitis 19.1% (placebo 29.8%)
multiple sclerosis relapse 17% (placebo 36.2%)
insomnia 6.4% (placebo 2.1%)
NCT01440101 · Phase 2/3 · registry result, not featured evidence
headache 25% (placebo 0%)
nasopharyngitis 25% (placebo 29.8%)
cystitis 16.7% (placebo 0%)
NCT01440101 · Phase 2/3 · registry result, not featured evidence
nasopharyngitis 50.5%
multiple sclerosis relapse 21.6%
influenza 12.4%
NCT01416155 · Phase 2 · registry result, not featured evidence
300 mg IV every 4 weeks
nasopharyngitis 4.5%
abdominal pain 0%
arthralgia 0%
NCT01405820 · Phase 2 · registry result, not featured evidence
300 mg IV every 4 weeks
nasopharyngitis 24.1%
multiple sclerosis relapse 14.8%
urinary tract infection 14.8%
NCT01405820 · Phase 2 · registry result, not featured evidence
300 mg IV every 12 weeks
multiple sclerosis relapse 2.4%
nasopharyngitis 2.4%
abdominal pain 0%
NCT01405820 · Phase 2 · registry result, not featured evidence
300 mg IV every 12 weeks
multiple sclerosis relapse 25%
nasopharyngitis 15.4%
headache 13.5%
NCT01405820 · Phase 2 · registry result, not featured evidence
300 mg SC every 12 weeks
abdominal pain 0%
arthralgia 0%
back pain 0%
NCT01405820 · Phase 2 · registry result, not featured evidence
300 mg SC every 4 weeks
bronchitis 5.7%
influenza 2.9%
nasopharyngitis 2.9%
NCT01405820 · Phase 2 · registry result, not featured evidence
300 mg SC every 12 weeks
multiple sclerosis relapse 32.1%
nasopharyngitis 17%
headache 9.4%
NCT01405820 · Phase 2 · registry result, not featured evidence
300 mg SC every 4 weeks
headache 20%
nasopharyngitis 17.8%
fatigue 13.3%
NCT01405820 · Phase 2 · registry result, not featured evidence
150 mg IV every 12 weeks
multiple sclerosis relapse 7.1%
influenza 2.4%
abdominal pain 0%
NCT01405820 · Phase 2 · registry result, not featured evidence
150 mg SC every 12 weeks
influenza 9.4%
multiple sclerosis relapse 6.3%
nasopharyngitis 6.3%
NCT01405820 · Phase 2 · registry result, not featured evidence
150 mg IV every 12 weeks
multiple sclerosis relapse 25.5%
influenza 17%
nasopharyngitis 17%
NCT01405820 · Phase 2 · registry result, not featured evidence
150 mg SC every 12 weeks
multiple sclerosis relapse 13.2%
headache 10.5%
nasopharyngitis 10.5%
NCT01405820 · Phase 2 · registry result, not featured evidence
nasopharyngitis 24.4% (placebo 11.9%)
headache 17.8% (placebo 7.1%)
dizziness 6.7% (placebo 0%)
NCT01071083 · Phase 2 · registry result, not featured evidence
headache 19.6%
fatigue 17.9%
upper respiratory tract infection 17.9%
NCT00516893 · Phase 2 · registry result, not featured evidence
pruritis 5%
NCT01071512 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 23 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

natalizumab

New or Newly Enlarging T2 Lesions 0.05 count @ 72wkIV Q4W
event count · count
Extension (open-label)
No placebo or comparator arm
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 7 more results
0.2 count @ 72wkIV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 count @ 24wkIV Q4W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 count @ 24wkIV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 count @ 48wkIV Q4W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0.1 count @ 48wkIV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 countIV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 countSC Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Time to First Relapse NA monthsIV Q4W
time to event · months
Extension (open-label)
No placebo or comparator arm
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 3 more results
NA monthsIV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
NA monthsIV Q6W then SC Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
NA monthsSC Q6W then IV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Annualized Relapse 0.0001 per year @ 72wkIV Q4W
event rate · per year
Extension (open-label)
No placebo or comparator arm
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
0.0001 per year @ 72wkIV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Time to EDSS Worsening NA monthsIV Q4W
time to event · months
Extension (open-label)
No placebo or comparator arm
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
NA monthsIV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
New T1 Hypointense Lesions 0 count @ 24wkIV Q4W
event count · count
Extension (open-label)
No placebo or comparator arm
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 7 more results
0 count @ 24wkIV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 count @ 48wkIV Q4W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 count @ 48wkIV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 count @ 72wkIV Q4W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 count @ 72wkIV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 countIV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 countSC Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
New Gd Enhancing Lesions 0 count @ 24wkIV Q4W
event count · count
Extension (open-label)
No placebo or comparator arm
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 7 more results
0 count @ 24wkIV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 count @ 48wkIV Q4W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 count @ 48wkIV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 count @ 72wkIV Q4W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0.1 count @ 72wkIV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 countIV Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0 countSC Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
EDSS 0.02 scoreIV Q6W
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
0.1 scoreSC Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Brain Volume -0.11% (n=112)IV Q6W
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
-0.1% (n=108)SC Q6W
NCT03689972 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Disability Progression 0% (n=3) @ 52wk
event count · % of participants
No placebo or comparator arm
NCT03046251 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted
EDSS 1.8 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT03046251 · Phase 4 · registry result, not featured evidence
show 1 more result
-0.19 score @ 36wk
NCT00516893 · Phase 2 · registry result, not featured evidence
Relapse Free 50% (n=4) @ 52wk
event count · % of participants
No placebo or comparator arm
NCT03046251 · Phase 4 · registry result, not featured evidence · converted to % from 2 Participants as posted
T100T -1.2 seconds @ 24wk
absolute change · seconds
No placebo or comparator arm
Change from Baseline at Week 24; n=207
NCT00871780 · Phase 4 · registry result, not featured evidence

+ 41 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: natalizumab's landscape · Tyruko (natalizumab-sztn)'s landscape